US FDA approves LaboPharm's anti-depressant Oleptro
This article was originally published in Scrip
Executive Summary
The US FDA has approved LaboPharm's once daily formulation of the antidepressant trazodone, known as Oleptro, for the treatment of major depressive disorder in adults, clearing the path for it to be launched later this year.